Acne VulgarisNCT05712837
Efficacy of 25% Trichloroacetic Acid Peel Versus 30% Salicylic Acid Peel in Mild to Moderate Acne Vulgaris
A study testing 25% TRICHLOROACETIC ACID and 30% salicylic acid in people with Acne Vulgaris, run by Combined Military Hospital Abbottabad at 1 site in Pakistan.
Trial summary
To compare the efficacy of 25% trichloroacetic acid peel versus 30% salicylic acid peel in mild to moderate acne vulgaris. Study Design: Randomized Control Trial. Place And Duration of Study: Department of Dermatology, CMH Abbottabad from 01 Jun 2022 to 30th Nov, 2022. Read more about this study
- Who is it for?
- Ages 13 to 22 yearsHealthy volunteers can take part
- Conditions the study is for
- Acne Vulgaris
- What is being tested?
- 25% TRICHLOROACETIC ACID and 30% salicylic acid
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 sitePakistan
- Study dates
- 1 Jun 2022to 30 Nov 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 13 to 22 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- Patients with mild or moderate facial acne vulgaris presented in dermatology opd
Who cannot join
- Patients with grade III or IV acne vulgaris
- patients taking any acne medications or had taken oral or topical medications in the past 4 weeks
- pregnant female patients or nursing a baby
- patients with known hypersensitivity to the formulations used in the study or a history of photosensitivity
- hypertrophic scars, keloidal tendency, active or recurrent herpes simplex infection
- active dermatosis
- unrealistic expectations
Trial locations and contacts
1 site in 1 country.
About this study
To compare the efficacy of 25% trichloroacetic acid peel versus 30% salicylic acid peel in mild to moderate acne vulgaris.
Study Design: Randomized Control Trial. Place And Duration of Study: Department of Dermatology, CMH Abbottabad from 01 Jun 2022 to 30th Nov, 2022.
Methodology: A total of 60 patients presented with mild or moderate acne vulgaris were randomized into two groups comprising 30 patients in each group and treated with either the TCA peel or the SA peel at 2-week intervals for 12 weeks. Patients in Group A were treated with 25% TCA peel whereas patients in Group B were treated with 30% SA peel. At the end of therapy after 12 weeks, evaluation of active acne was done by individual lesion counts (comedones, papules and pustules) and calculation of the Michaelsson acne score (MAS).
- Conditions
- Acne Vulgaris
- Being tested
- 25% TRICHLOROACETIC ACID, 30% salicylic acid
- Medical subject headings
- Acne Vulgaris
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
25% TRICHLOROACETIC ACIDDrug
Also called Peeling agent
Patients of group A were treated with 25% TCA peel and patients at 2-week intervals for a total of 12 weeks. Clinical evaluation was done at the end of therapy after 12-weeks of treatment.
30% salicylic acidDrug
Also called Peeling agent
Patients of group B were treated with 30 % salicylic acid peel and patients at 2 weeks interval for a total of 12 weeks.clinical evaluation was done at the end of therapy after 12 weeks of treatment
| Study group | Role | What they receive |
|---|---|---|
| Group A 25% TCA | Active comparator | 25% TCA peel Patients of group A were treated with 25% TCA peel and patients at 2-week intervals for a total of 12 weeks. Clinical evaluation was done at the end of therapy after 12-weeks of treatment. Receives: Drug: 25% TRICHLOROACETIC ACID |
| Group B 30% SALICYLIC ACID | Active comparator | 30% SA peels Patients of group B were treated with 30 % salicylic acid peel and patients at 2 weeks interval for a total of 12 weeks.clinical evaluation was done at the end of therapy after 12 weeks of treatment Receives: Drug: 30% salicylic acid |
What is being measured
The primary outcome is the main question the study is designed to answer.
Effectiveness of 25 % trichloroacetic acid peel versus 30 % salicylic acid peel in the treatment of mild to moderate acne vulgaris
Michaelson acne scores (MAS) Michaelson acne scores (MAS) was used to measure the effectiveness of both peels
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Feb 2023
- Study start1 Jun 2022
- Primary completion30 Nov 2022
- Study completion30 Nov 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acne VulgarisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Combined Military Hospital Abbottabad
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr kiran gul, Combined Military Hospital Abbottabad
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05712837
- Sponsor's protocol ID
- CMHAtd-ETH-15-Derm-22
- Status last verified
- Jan 2023
- First submitted
- 18 Jan 2023
- Last updated
- 6 Feb 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of 25% Trichloroacetic Acid Peel Versus 30% Salicylic Acid Peel in Mild to Moderate Acne Vulgaris
- ClinicalTrials.gov ID
- NCT05712837
- Acronym / sponsor ID
- CMHAtd-ETH-15-Derm-22
- Conditions
- Acne Vulgaris
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Combined Military Hospital AbbottabadUniversity, hospital or other
- Study start
- 1 Jun 2022 (actual)
- Primary completion
- 30 Nov 2022 (actual)
- Study completion
- 30 Nov 2022 (actual)
- First posted
- 6 Feb 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To compare the efficacy of 25% trichloroacetic acid peel versus 30% salicylic acid peel in mild to moderate acne vulgaris.
Study Design: Randomized Control Trial. Place And Duration of Study: Department of Dermatology, CMH Abbottabad from 01 Jun 2022 to 30th Nov, 2022.
Methodology: A total of 60 patients presented with mild or moderate acne vulgaris were randomized into two groups comprising 30 patients in each group and treated with either the TCA peel or the SA peel at 2-week intervals for 12 weeks. Patients in Group A were treated with 25% TCA peel whereas patients in Group B were treated with 30% SA peel. At the end of therapy after 12 weeks, evaluation of active acne was done by individual lesion counts (comedones, papules and pustules) and calculation of the Michaelsson acne score (MAS).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group A 25% TCA | Active comparator | Drug: 25% TRICHLOROACETIC ACID25% TCA peel Patients of group A were treated with 25% TCA peel and patients at 2-week intervals for a total of 12 weeks. Clinical evaluation was done at the end of therapy after 12-weeks of treatment. |
| Group B 30% SALICYLIC ACID | Active comparator | Drug: 30% salicylic acid30% SA peels Patients of group B were treated with 30 % salicylic acid peel and patients at 2 weeks interval for a total of 12 weeks.clinical evaluation was done at the end of therapy after 12 weeks of treatment |
Who may qualify
- Ages
- 13 to 22 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (1 listed)
- Patients with mild or moderate facial acne vulgaris presented in dermatology opd
Key exclusion criteria (7 listed)
- Patients with grade III or IV acne vulgaris
- patients taking any acne medications or had taken oral or topical medications in the past 4 weeks
- pregnant female patients or nursing a baby
- patients with known hypersensitivity to the formulations used in the study or a history of photosensitivity
- hypertrophic scars, keloidal tendency, active or recurrent herpes simplex infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 25% TRICHLOROACETIC ACIDAlso: Peeling agentPatients of group A were treated with 25% TCA peel and patients at 2-week intervals for a total of 12 weeks. Clinical evaluation was done at the end of therapy after 12-weeks of treatment. | Drug | Group A 25% TCA |
| 30% salicylic acidAlso: Peeling agentPatients of group B were treated with 30 % salicylic acid peel and patients at 2 weeks interval for a total of 12 weeks.clinical evaluation was done at the end of therapy after 12 weeks of treatment | Drug | Group B 30% SALICYLIC ACID |
Primary outcome
Effectiveness of 25 % trichloroacetic acid peel versus 30 % salicylic acid peel in the treatment of mild to moderate acne vulgaris
Time frame: 12 weeks
Michaelson acne scores (MAS) Michaelson acne scores (MAS) was used to measure the effectiveness of both peels
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Feb 2023.
Related trials for Acne Vulgaris
Not yet recruitingPhase 3
Evaluation of the Efficacy and Safety of Fractional CO₂ Laser With and Without Intradermal Botulinum Toxin A in the Treatment of Inflammatory Facial Acne Vulgaris.
Acne, Acne Papulopustulosa
RecruitingPhase 4
Safety, Tolerability, and Clinical Effectiveness of Adapalene/Clindamycin Phosphate Gel (Klenzit®-C) in Vietnamese Patients With Mild to Moderate Acne Vulgaris
Acne
RecruitingPhase 3
Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)
Acne Vulgaris
RecruitingPhase 4
Comparing Nadifloxacin Plus Tretinoin Versus Clindamycin Plus Tretinoin Creams for Mild-to-Moderate Acne
Acne Vulgaris
Active, not recruiting
Clinical Study to Evaluate the Safety and Efficacy of Candela Technology
Hair Reduction, Tattoo Removal
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 25% TRICHLOROACETIC ACID and 30% salicylic acid in people with Acne Vulgaris, run by Combined Military Hospital Abbottabad at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Effectiveness of 25 % trichloroacetic acid peel versus 30 % salicylic acid peel in the treatment of mild to moderate acne vulgaris (time frame: 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Feb 2023.